Low molecular weight heparin in acute coronary syndromes
- Christopher P. Cannon MD
- … show all 1 hide
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Traditionally, unfractionated heparin has played an important role in the treatment of acute coronary syndromes. Low molecular weight heparin (LMWH), is a promising new type of heparin, which is fractionated to include only heparin molecules of lower molecular weight. LMWHs are administered subcutaneously and do not require monitoring of the activated partial thromboplastin time, making them much easier to use. LMWHs are combined inhibitors of both thrombin and Factor Xa inhibitors. Several recent large trials in unstable angina and non-Q wave myocardial infarction have shown that LMWH is effective, and one agent has been shown to be superior to unfractionated heparin in reducing death, myocardial infarction, or recurrent angina. They also are very low cost (approximately $50 per day) and appear to be very cost effective in the treatment of unstable angina. Thus, LMWHs appear to be the new anticoagulant agent in acute coronary syndromes.
- Antman EM, Braunwald E: Acute myocardial infarction. In Heart Disease. A Textbook of Cardiovascular Medicine, vol. 1, edn. 5. Edited by Braunwald E. Philadelphia: WB Saunders; 1997:1184–1288.
- Fuster V, Badimon L, Badimon JJ, Chesebro JH: The pathophysiology of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992, 326:242–250,310-318. CrossRef
- Cannon CP: Optimizing the treatment of unstable angina. J Thromb Thrombolysis 1995, 2:205–218. CrossRef
- Tollefsen DM: Heparin: Basic and clinical pharmacology. In Hematology: Basic principles and practice, vol 1. Edited by Hoffman R, Benz EJJ, Shattil SJ, Furie B, Cohen HJ. New York: Churchill Livingstone; 1991:1436–1445.
- Verstraete M: Heparin. In Cardiovascular drug therapy, vol 1. Edited by Messerli FH. Philadelphia: WB Saunders; 1990:1457–1469.
- Rosenberg RD: The heparin-antithrombin system: a natural anticoagulant mechanism. In Hemostasis and Thrombosis: Basic Principles and Clinical Practice, edn 2. Edited by Colman RW, Marder VJ, Salzman EW, Hirsh J. Philadelphia: JB Lippincott; 1987:1373–1392.
- Hirsh J: Heparin. N Engl J Med 1991, 324:1565–1574. CrossRef
- Ogilby JD, Untereker WJ, Corin WJ, et al.: Variability of effective anticoagulation for PTCA is dependent upon heparin potency.(abstract) Circulation 1991, 84(Suppl II):II-592.
- Young E, Prins M, Levine MN, Hirsh J: Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemostas 1992, 67:639–643.
- Bock PE, Juscombe M, Marshall SE, et al.: The multiple complexes formed by the interaction of platelet factor 4 with heparin. Biochem J 1980, 191:769–776.
- Lijnen HR, Hoylaerts M, Collens D: Heparin binding properties of human histidine-rich glycoprotein: mechanism and role in the neutralization of heparin in plasma. J Biol Chem 1983, 258:3803–3808.
- Preissner KT, Muller-Berghaus G: Neutralization and binding of heparin by S-protein/vitronectin in the inhibition of factor Xa by antithrombin III. J Biol Chem 1987, 262:12247–12253.
- Maraganore JM, Bourdon P, Adelman B, et al.: Heparin variability and resistance: Comparisons with a direct thrombin inhibitor [abstract]. Circulation 1992, 86 (Suppl. I):I-386.
- Williams DO, Kirby MG, McPhearson K, Phear DN: Anticoagulant treatment in unstable angina. Br J Clin Pract 1986, 40:114–116.
- Telford AM, Wilson C: Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate coronary syndrome. Lancet 1981, 1:1225–1228. CrossRef
- Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin or both to treat unstable angina. N Engl J Med 1988, 319:1105–1111. CrossRef
- Theroux P, Waters D, Lam J, et al.: Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 1992, 327:141–145. CrossRef
- Theroux P, Waters D, Qiu S, et al.: Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina. Circulation 1993, 88:2045–2048.
- The RISC Group: Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990, 336:827–830. CrossRef
- Cohen M, Adams PC, Parry G, et al.: Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Circulation 1994, 89:81–88.
- Braunwald E, Mark DB, Jones RH, et al.: Unstable Angina: Diagnosis and Management. Clinical Practice Guideline Number 10. Rockville, MD: Agency for Health Care Policy and Research and the National Heart, Lung, and Blood Institute, Public Health Service, US Department of Health and Human Services; 1994:154.
- Hirsh J, Fuster V: Guide to anticoagulation therapy. Part 1: Heparin. Circulation 1994, 89:1449–1468.
- Hirsh J, Levine M: Low molecular weight heparin. Blood 1993, 79:1–17.
- Antman EM, for the TIMI 9B Investigators: Hirudin in acute myocardial infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation 1996, 94:911–921.
- Zoldhelyi P, Bichler J, Owen WG, et al.: Persistent thrombin generation in humans during specific thrombin inhibition with hirudin. Circulation 1994, 90:2671–2678.
- Warkentin TE, Levine MN, Hirsh J, et al.: Heparininduced thrombocytopenia in patients treated with lowmolecular-weight heparin or unfractionated heparin. N Engl J Med 1995, 332:1330–1335. CrossRef
- Gold HK, Torres FW, Garabedian HD, et al.: Evidence of a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris. J Am Coll Cardiol 1993, 21:1039–1047. CrossRef
- Granger CB, Miller JM, Bovill EG, et al.: Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. Circulation 1995, 91:1929–1935.
- Turpie AG, Levine MN, Hirsh J, et al.: A randomized controlled trial of a low-molecular weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med 1986, 315:925–929. CrossRef
- Levine MN, Hirsh J, Gent G, et al.: Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann Intern Med 1991, 114:545–551.
- Pezzuoli G, Neri S, G.G., Settembrini P, et al.: Prophylaxis of fatal pulmonary embolism in general surgery using lowmolecular weight heparin Cy 216: a multicentre, doubleblind, randomized, controlled, clinical trial versus placebo (STEP). Int Surg 1989, 74:205–210.
- Hull RD, Raskob GE, Pineo GF, et al.: Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992, 326:975–982. CrossRef
- Prandoni P, Lensing AW, Muller HR, et al.: Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in the treatment of proximalvein thrombosis. Lancet 1992, 339:441–445. CrossRef
- Levine M, Gent M, Hirsh J, et al.: A comparison of lowmolecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996, 334:677–681. CrossRef
- Koopman MMW, Prandoni P, Piovella F, et al.: Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin admistered at home. N Engl J Med 1996, 334:682–687. CrossRef
- Nesvold A, Kontny F, Abildgaard U, Dale J: Safety of high doses of low molecular weight heaprin (Fragmin) in acute myocardial infarction. A dose-finding study. Thrombosis Res 1991, 64:579–587. CrossRef
- Gurfinkel R, Mejail R, Dutonto E, et al.: Heparina de bajo peso molecular en la angina inestable. Estudio piloto. Cardiologia Intercontinental 1994, 3:83–86.
- Gurfinkel EP, Manos EJ, Mejail RI, et al.: Low molecular weight heparin versis regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol 1995, 26:313–318. CrossRef
- Fragmin during Instability in Coronary Artery Disease (FRISC) Study Group: Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996, 347:561–568.
- Oler A, Whooley MA, Oler J, Grady D: Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA 1996, 276:811–815. CrossRef
- Klein W, Buchwald A, Hillis SE, et al.: Comparison of low-molecular-weight hepairn with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in Unstable Coronary Artery Disease Dtudy (FRIC). Circulation 1997, 96:61–68.
- Cohen M, Demers C, Gurfinkel EP, et al.: A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997, 337:447–452. CrossRef
- The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators. Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A. J Am Coll Cardiol 1997, 29:1474–1482. CrossRef
- •• Antman EM, McCabe CH, Premmereur J, et al.: Enoxaparin for the acute and chronic management of unstable angina/non-Q wave myocardial infarction: results of TIMI 11B [abstract]. Circulation 1998, 98(Suppl I):I-504.
- •• Antman EM, Cohen M, Radley D, et al.: Enoxaparin for unstable angina/non-Q wave myocardial infarction: Meta-analysis of TIMI 11B and ESSENCE [abstract]. J Am Coll Cardiol 1999, 33(Suppl A):351A.
- Faxon DP, Spiro TE, Minor S, et al.: Low molecular weight heparin in prevention of restenosis after angioplasty. Results of Enoxaparin Restenosis (ERA) trial. Circulation 1994, 90:908–914.
- Goods CM, Liu MW, Jain SP, et al.: Low molecular weight heparin versus standard heparin in patients at high risk for stent thrombosis: clinical outcomes [abstract]. Circulation 1996, 94(Suppl I):I-684.
- Baird SH, McBride SJ, Trouton TG, Wilson C: Low-molecularweight heparin versus unfractionated heparin following thrombolysis in myocardial infarction [abstract]. J Am Coll Cardiol 1998, 31(Suppl A):191A. CrossRef
- Frostfeldt G, Ahlberg G, Gustafsson G, et al.: Low molecular weight heparin (dalteparin) as adjuvant treatment of thrombolysis in acute myocardial infarction--a pilot study: biochemical markers in acute coronary syndromes (BIOMACS II). J Am Coll Cardiol 1999, 33(3):627–633. CrossRef
- Low molecular weight heparin in acute coronary syndromes
Current Cardiology Reports
Volume 1, Issue 3 , pp 206-211
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links
- Author Affiliations
- 1. Cardiovascular Division, Brigham and Women’s Hospital, 75 Francis Street, 02115-6195, Boston, MA, USA